Outcome and Follow-up
Over one month, her skin rash and pruritus significantly improved
(Figure 2) without adverse effects with dupilumab use, permitting a
tapered discontinuation of prednisone. Patient’s eczema is adequately
managed with dupilumab maintenance dose and continual application of
emollients, and topical hydrocortisone 2.5% on face, triamcinolone
0.1% on torso as needed. In concern of seizure, long-term
electroencephalogram (EEG) and further neurological workup of the
patient’s blinking spells did not reveal seizures or significant
findings. Six months since initiation of dupilumab, patient had an
incidence of pneumonia that resolved with antibiotics but otherwise no
other serious events.